LIF and hepatocellular carcinoma: Having established that CVB‐D functions as a LIF inhibitor with prominent anti‐tumor characteristics, we embarked on an in‐depth exploration of its efficacy and the underlying mechanisms through which it exerts inhibitory effects on HCC in vitro.